Lonza Pharma & Biotech – Engineering & Manufacture of Second Generation ADCs: Tools & Techniques
This webinar has taken place but is available to view here.
First-generation antibody drug conjugates (ADCs) have development challenges, including non-uniform and non-optimized drug-to-antibody ratios (DAR). Lonza’s Site Specific Conjugation (SSC) Vectors, designed for use with Lonza’s proprietary GS Xceed® System, are an effective way to produce conjugation-competent antibodies that have a defined number and location of bioconjugate attachment points. The SSC vectors allow a high degree of control over conjugation site, DAR and conjugation of cargoes in addition to cytotoxins.
In this webinar, we will present a case study based on a model Ab where we will describe how variants containing one or two engineered cysteine residues achieved high levels of homogeneity and DARs of 2 or 4, respectively. In vitro cytotoxicity and in vivo efficacy data will also be presented.
We will also outline a project plan taking an antibody with engineered cysteines to a second-generation ADC. We will highlight the hands-on approach to the adaptation and development of key process steps such as reduction, TFF, reoxidation, conjugation, filtration and formulation. Finally, we’ll provide insight on how to successfully make ADC processes fit for production and scale-up based on Lonza’s extensive ADC development and manufacture expertise.
Ramón Gómez de la Cuesta, Ph.D.
Principal Scientist, New Expression Technologies Group
Ramón Gómez de la Cuesta currently serves as Principal Scientist in Lonza’s New Expression Technologies Group where he has led several protein engineering projects. Ramón received his undergraduate degree from the University Autonóma of Madrid and an MSc in Applied Biomolecular Technology at the University of Nottingham where he became interested in Antibody Biotechnology, drug development and Advanced Structural Biology. After working as a Protein Scientist in Abbott Laboratories, he completed his Ph.D. at the University of Cambridge studying the mechanism of action of GTPase activating proteins in the Structural Biochemistry department.
Dr. rer. nat. Christoph Sklorz
Scientific Specialist, Bioconjugates
Christoph Sklorz joined Lonza in 2009 and moved to the Bioconjugates Process Development Group in 2010. During his time with this group, he has acquired experience with different conjugation technologies and drug-linker platforms. Prior to joining Lonza, Christoph held positions at Evotec OAI and Fluka (Sigma Aldrich). An organic chemist, Christoph attended the University of Cologne where he earned his Dipl-Chem in Chemistry.
As a leader for contract development and manufacturing, Lonza Pharma & Biotech is recognized for our reliable, high-quality services, global capacity, innovative technology platforms and extensive experience. Our broad capabilities span across biologics, small molecules, bioconjugates, and cell and gene therapies. We manage projects from pre-clinical through commercialization using expertise that covers both drug substance and drug product.